Publications

List of selected publications from Accuro Biologics scientists:

Jones TD, Hanlon M, Smith BJ, Heise CT, Nayee PD, Sanders DA, Hamilton A, Sweet C, Unitt E, Alexander G, Lo KM, Gillies SD, Carr FJ, Baker MP. The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J Interferon Cytokine Res. (2004), 24, 560-72.
Tehmina Amin & Graham Carter, Immunogenicity issues with therapeutic proteins. Current Drug Discovery. November 2004, p20-24
T. Parsons, I. Spendlove, R. Nirula, M. Writer, G. Carter, F. Carr & L.G. Durrant. A novel CEA vaccine stimulates T cell proliferation, IFN secretion and CEA specific CTL responses. Vaccine (2004), 22: 3487-3494
Durrant L, Parsons T, Moss R, Spendlove I, Carter G, & Carr F. Human antiidotypic antibodies can be good immunogens as they target Fc receptors on antigen presenting cells allowing efficient stimulation of both helper and cytotoxic T cell responses. International Journal of Cancer (2001), 92: 414-420
Walker N, Holley J, Naylor C, Flores-Diaz M, Alape-Giron A, Carter G, Carr F, Thelestam M, Keyte M, Moss D, Basak A, Miller J & Titball R. Identification of residues in the carboxy-terminal domain of Clostridium perfringens -toxin (phospholipase C) which are required for its biological activities. Archives of Biochemistry and Biophysics (2000), 384: 24-30
Hamilton AA, Adair JR, Forster SJ. Expression of antibody fusion proteins in mammalian cells. Expression of antibody fusion proteins in mammalian cells. Methods Mol Biol. (1998), 80, 427-38.
Carter G, White P, Fernie M, King S, McLean G, Titball R & Carr F. Enhanced antitumour effect of liposomal daunorubicin using antibody-phospholipase C conjugates or fusion protein. International Journal of Oncology (1998), 13: 819-825
Hamilton AA, Manuel DM, Grundy JE, Turner AJ, King SI, Adair JR, White P, Carr FJ, Harris WJ. A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections. J Infect Dis. (1997), 176, 59-68.
Graziano RF, Tempest PR, White P, Keler T, Deo Y, Ghebremariam H, Coleman K, Pfefferkorn LC, Fanger MW, Guyre PM. Construction and characterization of a humanized anit-gamma-Ig receptor type I (FC gamma RI) monoclonal antibody J. Immunol. (1995) 155: 4996-5002
Tempest PR, White P, Buttle M, Carr FJ, Harris WJ. Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus. Int. J. Biol. Macromol. (1995) 17: 37-42
Armour KL, Tempest PR, Fawcett PH, Fernie ML, King SI, White P, Taylor G, Harris WJ. Sequences of heavy and light chain variable regions from four bovine immunoglobulins. Mol. Immunol. (1994) 31: 1369-1372
Tempest PR, White P, Williamson, ED, Titball RW, Kelly DC, Kemp GL, Gray PM, Forster SJ, Carr FJ, Harris WJ. Efficient generation of a reshaped human mAb specific for the alpha toxin of Clostridium perfringens. Protein Eng. (1994) 7:1501-1507
Tempest PR, Barbanti E, Bremner P, Carr FJ, Ghislieri M, Rifaldi B, Marcucci F. A humanized anti-tumour necrosis factor-alpha monoclonal antibody that acts as a partial, competitive antagonist of the template antibody. Hybridoma (1994) 13: 183-190
Taylor G, Furze J, Tempest PR, Bremner P, Carr FJ, Harris WJ. Humanised monoclonal antibody to respiratory syncytial virus. Lancet (1991) 337: 1411- 1412
Simon J Forster, Francis J Carr, William J Harris and Anita A Hamilton. "Expression of Foreign Genes in Mammalian Cells. Using an Antibody Fusion System Methods in Molecular Biology, Vol.10: Immunochemical Protocols Ed M Manson 1991 The Human Press, Inc.
Tempest PR, Bremner P, Lambert M, Taylor G, Furze JM, Carr FJ, Harris WJ. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (1991) 9: 266-271

List of selected patents of which Accuro Biologics scientists are co-inventors:

Publication No.	Title	Applicant / Sponsor
WO2005002529	Immunogenicity-reduced anti-CR1 antibody and compositions and methods of treatment based thereon	E-site
WO2005042581	Modified anti-CD52 antibody	Biovation
EP1524275	Deimmunised binding molecules to CD3	Micromet
WO2005040220	Multispecific deimmunised CD3-binders	Micromet
WO2005023872	Antibodies against interleukin-1 receptor and uses thereof	Roche
W02004108158	De-immunised anti-CD3 antibody	Alexion
WO03/000736	Humanised antibodies derived form DD-3B6/22 specific for the D-dimer fragment of fibrin	Agen
WO02/0988897	Modified antibodies to prostate-specific membrane antigen	Cornell
WO02/069232	Method for identification of T cell epitopes and use for preparing molecules with reduced immunogenicty	Biovation
WO02/066514	Artificial fusion proteins with reduced immunogenicity	Merck KGaA
WO02/066058	Modified anti-EGFR antibodies with reduced immunogenicity	Merck KGaA
WO94/09136	Recombinant humanised anti-cytomegalovirus antibodies	Scotgen